Vascularization and restoration of heart function in rat myocardial infarction using transplantation of human cbMSC/HUVEC core-shell bodies

Lee, Wen-Yu; Wei, Hao-Ji; Wang, Jiun‐Jie; Lin, Kun‐Ju; Lin, Wei-Wen; Chen, Ding-Yuan; Huang, Chieh‐Cheng; Lee, Ting‐Yin; Ma, Hsiang-Yang; Hwang, Shiaw-Min; Chang, Yen; Sung, Hsing‐Wen

doi:10.1016/j.biomaterials.2011.11.059

Cited by 27 publications

(28 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conventional strategies such as overexpression of prosurvival genes, such as Akt, β adrenergic stimulation, cotransplanting with others, such as the endothelial cells, modification of the extracellular matrix and immune system are used to enhance survival and retention of CPCs in the heart. [113][114][115][116][117][118][119] Recently, there has been increasing focus on development of novel biomaterials that are coated with stem cells are functionalized with growth, mitotic and chemotactic factors, cytokines, and other biologically active materials. These new biomaterials are biocompatible and biodegradable polymers made of poly (d, l-lactide-co-glycolide acid) or poly(lactic-co-glycolic acid) that allow prolonged and controlled delivery of growth factors in situ and better cell retention in the transplanted area.…”

Section: Novel Delivery Systems For Stem Cell Therapymentioning

confidence: 99%

Recent Developments in Cardiovascular Stem Cells

Madonna

Ferdinándy

Caterina

et al. 2014

Circulation Research

View full text Add to dashboard Cite

45Human embryonic stem cells have been shown to differentiate to beating cardiomyocytes, SA nodal-like cells and mesodermal Recent Developments in Cardiovascular Research:The goal of "Recent Developments" is to provide a concise but comprehensive overview of new advances in cardiovascular research, which we hope will keep our readers abreast of recent scientific discoveries and facilitate discussion, interpretation, and integration of the findings. This will enable readers who are not experts in a particular field to grasp the significance and effect of work performed in other fields. It is our hope and expectation that these "Recent Development" articles will help readers to gain a broader awareness and a deeper understanding of the status of research across the vast landscape of cardiovascular research-The Editors. 50 Moreover, the use of induced pluripotent stem cell-derived cardiac myocytes for cardiac repair is hampered by their immature phenotype and the presence of epigenetic and genetic changes.24,51,52 Resident and bone marrow cells and cortical bone-derived cells are considered as potential sources for differentiation to cardiac myocytes but lacking compelling evidence for cardiac myogenesis and perhaps exerting their salutary biological effects through paracrine mechanisms. 19,29,[53][54][55][56][57][58] Equally exciting and challenging are the discovery and characterization of other CPCs that could give raise to various cardiac cells types, including smooth muscle cells, endothelial cells, and fibroblasts. [59][60][61][62][63] An important problem to overcome is the multiple comorbidities and their comedications of ischemic heart disease patients with heart failure that may affect cytoprotective signaling triggered by the different stem cell, as well as survival and differentiation properties of such stem cells in the injured tissue. [64][65][66] Clearly, the rapid face of discoveries is dazzling and a complete coverage of the recent developments in cardiovascular stem cells would be beyond the scope of this article. We regret that many valuable works were not covered in part or at all included in the present overview on Recent Developments. Clinical Trials In Human PatientsThe ClinicalTrials.gov lists >1000 clinical trials including >600 studies in the United States alone that tests effects of various stem cells in human patients (http://www.clinicaltrials. gov/). The list includes 71 including 38 active clinical trials in patients with heart failure using various stem cells, such as adipose-derived, mesenchymal, human embryonic, autologous CD133 + and CD34 + stem cells among the others.18,67-74Autologous skeletal myoblasts were probably the first cell type used to regenerate functional myocardium. It was tested initially in a rabbit model of myocardial cryoinjury, which showed incorporation of the injected myoblasts and improved myocardial performance. 75 Subsequent observational studies were followed by randomized clinical trials in human patients with heart failure injected with autologous skele...

show abstract

Section: Novel Delivery Systems For Stem Cell Therapymentioning

confidence: 99%

Recent Developments in Cardiovascular Stem Cells

Madonna

Ferdinándy

Caterina

et al. 2014

Circulation Research

View full text Add to dashboard Cite

show abstract

“…Many clinical studies (clinicaltrials.gov) exploit the immunomodulatory and regenerative capacities [1][2][3][4][5][6] of multipotent mesenchymal stem cells (MSC). 7,8 However, the role of MSC in regenerative medicine is not fully understood and their direct or paracrine effects remain to be clarified.…”

Section: Introductionmentioning

confidence: 99%

Labeling of mesenchymal stem cells for MRI with single-cell sensitivity

Schellenberger¹,

Kratz²,

Farr³

et al. 2016

IJN

View full text Add to dashboard Cite

Sensitive cell detection by magnetic resonance imaging (MRI) is an important tool for the development of cell therapies. However, clinically approved contrast agents that allow single-cell detection are currently not available. Therefore, we compared very small iron oxide nanoparticles (VSOP) and new multicore carboxymethyl dextran-coated iron oxide nanoparticles (multicore particles, MCP) designed by our department for magnetic particle imaging (MPI) with discontinued Resovist ® regarding their suitability for detection of single mesenchymal stem cells (MSC) by MRI. We achieved an average intracellular nanoparticle (NP) load of >10 pg Fe per cell without the use of transfection agents. NP loading did not lead to significantly different results in proliferation, colony formation, and multilineage in vitro differentiation assays in comparison to controls. MRI allowed single-cell detection using VSOP, MCP, and Resovist ® in conjunction with high-resolution T2*-weighted imaging at 7 T with postprocessing of phase images in agarose cell phantoms and in vivo after delivery of 2,000 NP-labeled MSC into mouse brains via the left carotid artery. With optimized labeling conditions, a detection rate of ~45% was achieved; however, the experiments were limited by nonhomogeneous NP loading of the MSC population. Attempts should be made to achieve better cell separation for homogeneous NP loading and to thus improve NP-uptake-dependent biocompatibility studies and cell detection by MRI and future MPI. Additionally, using a 7 T MR imager equipped with a cryocoil resulted in approximately two times higher detection. In conclusion, we established labeling conditions for new high-relaxivity MCP, VSOP, and Resovist ® for improved MRI of MSC with single-cell sensitivity.

show abstract

“…[6][7][8][9] Improved engineered vasculature would allow ischemic and traumatic tissue defects to be treated more effectively and efficiently. [9][10][11][12][13] The insulin super-family is composed of 10 members in mammals, insulin, 2 insulin-like growth factors, 3 relaxin proteins, and 4 insulinlike peptides. Sequence conservation is minimal; the major commonality is structural, as they all have 3 characteristic disulfide bonds.…”

Section: Vascular Endothelial Growth Factor (Vegf) a And Fibroblast mentioning

confidence: 99%

Enhancing engineered vascular networks in vitro and in vivo: The effects of IGF1 on vascular development and durability

et al. 2017

View full text Add to dashboard Cite

Objectives: Creation of functional, durable vasculature remains an important goal within the field of regenerative medicine. Engineered biological vasculature has the potential to restore or improve human tissue function. We hypothesized that the pleotropic effects of insulin-like growth factor 1 (IGF1) would enhance the engineering of capillary-like vasculature. Results: IGF1 supplementation significantly enhanced de novo vasculogenesis both in vitro and in vivo. Effects were long-term as they lasted the duration of the study period, and included network density, vessel length, and diameter. Bifurcation density was not affected. However, the highest concentrations of IGF1 tested were either ineffective or even deleterious. Sustained IGF1 delivery was required in vivo as the inclusion of recombinant IGF1 protein had minimal impact.Conclusion: IGF1 supplementation can be used to produce neovasculature with significantly enhanced network density and durability. Its use is a promising methodology for engineering de novo vasculature to support regeneration of functional tissue.

show abstract

Vascularization and restoration of heart function in rat myocardial infarction using transplantation of human cbMSC/HUVEC core-shell bodies

Cited by 27 publications

References 35 publications

Recent Developments in Cardiovascular Stem Cells

Recent Developments in Cardiovascular Stem Cells

Labeling of mesenchymal stem cells for MRI with single-cell sensitivity

Enhancing engineered vascular networks in vitro and in vivo: The effects of IGF1 on vascular development and durability

Contact Info

Product

Resources

About